# A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

> **NCT04732598** · PHASE3 · COMPLETED · sponsor: **Japanese Foundation for Cancer Research** · enrollment: 281 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel + bevacizumab therapy
- **DRUG:** Paclitaxel + bevacizumab + atezolizumab

## Key facts

- **NCT ID:** NCT04732598
- **Lead sponsor:** Japanese Foundation for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-21
- **Primary completion:** 2025-09-12
- **Final completion:** 2026-03-13
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732598, "A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04732598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*